Disease Domain | Count |
---|---|
Infectious Diseases | 5 |
Neoplasms | 3 |
Nervous System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Prophylactic vaccine | 3 |
Drug conjugates | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism Potassium channel blockers |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HPK1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SERT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Oct 2024 |
Sponsor / Collaborator |
Start Date12 Oct 2023 |
Sponsor / Collaborator |
Start Date15 Aug 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fructose-1,6-Bisphosphate Aldolase Covalent Inhibitors(Central China Normal University) ( ALDO ) | Mycoses More | Preclinical |
SH-337 ( Potassium channel ) | - | Preclinical |
Pam3CSK4-RBD ( ACE2 ) | COVID-19 More | Preclinical |
HPK1 inhibitors(Central China Normal University) ( HPK1 ) | Neoplasms More | Preclinical |
GAP112-RBD ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |